Events

Events

Kodiak Sciences Investor R&D Day Presentation

Clinical Program Overview October 2024

Upcoming Events

Past Events
Innovate Retina 2024
October 17, 2024 1:30 PM PDT

Presentation and Panel details are below:

 

•Presentation Title: Update on Antibody Biopolymer Conjugates: Optimizing Immediacy and Durability
Time: 3:30 PM CT
Presenter: Mark Barakat, M.D., FASRS, Clinical Assistant Professor of Ophthalmology, University of Arizona College of Medicine – Phoenix; Founder and Director of Research, Retina Macula Institute of Arizona; Medical Director, Spectra Eye Institute

 

•Panel Title: The Future of Retinal Therapeutics 
Time: 6:30 PM CT
Kodiak Panelist: Victor Perlroth, M.D., Chairman and Chief Executive Officer 
 

Kodiak Sciences Investor R&D Day
September 23, 2024

Notes

View Investor R&D Day  Presentation (Slides) 

Investor R&D Day

Watch Investor R&D Day  Video (Webcast) 

Investor R&D Day Presentation (Video)

Table of Contents

ChaptersSpeakerTimestamp
Opening RemarksVictor Perlroth, MD, Chairman and CEO of Kodiak0:00:09
Welcome & IntroductionsVictor Perlroth, MD0:03:00
Why Kodiak?Victor Perlroth, MD0:07:50
Science of DurabilityDavid Brown, MD, Retina Specialist and Key Opinion Leader0:25:21
Science of the Enhanced FormulationDavid Brown, MD0:41:16
Audience Q&AAll0:50:09
Clinical Program OverviewCharles Wykoff, MD, PhD, Retina Specialist and Key Opinion Leader0:58:07
The Kodiak OpportunityVictor Perlroth, MD1:21:52
ABCD Platform PreviewDolly Chang, MD, PhD, Chief Scientific Officer of Kodiak1:34:40
Summary & TakeawaysVictor Perlroth, MD1:45:55
Audience Q&AAll1:47:44

 

Clinical Trials at the Summit 2024 meeting
June 8, 2024 from 8:00 AM to 5:30 PM MDT

Presentations on Kodiak's clinical pipeline will be given at the meeting. Specifics of the presentations are below:

Title: Bispecific Anti-IL-6 Anti-VEGF Programs: KSI-501 in Retinal Vascular Disease and KSI-101 in Macular Edema Secondary to Inflammation
Time: 7:49 – 7:53 AM MT
Presenter: Quan Dong Nguyen, M.D., Professor of Ophthalmology and Director of Uveitis and Ocular Inflammation, Byers Eye Institute, Stanford University School of Medicine.

View Presentation

 

 

Title: Update on KSI Programs for Retinal Diseases
Time: 1:10 – 1:14 PM MT
Presenter: Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences

View Presentation
Angiogenesis, Exudation, and Degeneration 2024 virtual meeting
February 3, 2024 3:30 PM EST

Title: KSI-501 Bispecific Anti-VEGF Anti-IL-6 Antibody Biopolymer Conjugate: First Time Results of the Multiple Ascending Dose Phase 1 Study

Presenter: Mark R. Barakat, M.D., Managing Partner and Director of Clinical Research, Retina Macula Institute of Arizona, Clinical Assistant Professor of Ophthalmology, University of Arizona College of Medicine, Phoenix, AZ

56th Annual Scientific Meeting of the Retina Society
October 18, 2023

Title: Tarcocimab tedromer (KSI-301) 5 mg for the treatment of wAMD: One-year primary efficacy and safety outcomes of the Phase 3 DAYLIGHT Study
Presentation Date and Time: October 13, 2023; 8:52 AM ET
Presenter: Brandon Busbee, M.D., Tennessee Retina and Retina Consultants of America
View Presentation

 

Title: Tarcocimab tedromer (KSI-301) Anti-VEGF Antibody Biopolymer Conjugate for Diabetic Macular Edema: Primary Endpoint Efficacy and Safety Outcomes of the GLEAM and GLIMMER Phase 3 Pivotal Studies
Presentation Date and Time: October 13, 2023; 10:28 AM ET
Presenter: Robert Wong, M.D., FASRS, Austin Retina Associates

View Presentation

 

Title: Tarcocimab tedromer (KSI-301) 5 mg for the treatment of RVO: One-year primary efficacy, durability, and safety outcomes of the Phase 3 BEACON Study
Presentation Date and Time: October 13, 2023; 10:38 AM ET
Presenter: Ankoor Shah, M.D., Retina Consultants of Texas

View Presentation

 

2022 American Academy of Ophthalmology Meeting, Retina Subspecialty
September 30, 2022 2:48 PM PDT
Title: KSI-301 Anti-VEGF Antibody Biopolymer Conjugate for Retinal Vein Occlusion: Primary and Secondary 24- Week Efficacy and Safety Outcomes of the BEACON Phase 3 Pivotal Study
Presenter: Michael A Singer, M.D., Clinical Professor of Ophthalmology, University of Texas Health Science Center, and Director of Clinical Research, Medical Center Ophthalmology Associates, San Antonio, TX
 
Retina World Congress 2022
May 13, 2022 2:14 PM PDT
Title: Results of the KSI-301 DAZZLE Neovascular AMD Pivotal Clinical Trial
Presenter: Carl Regillo, M.D., Chief of Retina Service, Wills Eye Hospital / Thomas Jefferson University, Philadelphia, PA
 
Third Quarter 2019 Business Highlights
November 12, 2019 2:00 PM PST

Kodiak management will provide regulatory updates on the company’s “2022 Vision” for KSI-301 following from a successful FDA end-of-phase 2 meeting held on October 30, 2019, and discuss new data from its on-going Phase 1b clinical study of KSI-301 as well as other business highlights for the third quarter ended September 30, 2019.

AAO 2019 Annual Meeting
October 12 - October 15, 2019

Retina Subspecialty Day: October 11-12, 2019
Friday, October 11, 2019
4:58pm PDT
Presentation by Charles C. Wykoff, MD, PhD
Extended Durability in Exudative Retinal Diseases Using the Novel Intravitreal Anti-VEGF Antibody Biopolymer Conjugate KSI-301: Results From the Phase 1b Study in Patients with wAMD, DME and RVO

EURetina 2019 Congress
September 5 - September 8, 2019

Thursday, September 5, 2019
11:59am CEST
Presentation by Pravin U. Dugel, MD

Session: Novelties and Late Breaking Developments in Retina & Technology

Title: Novel anti-VEGF antibody biopolymer conjugate KSI-301 with potential for extended durability in retinal vascular diseases: first-time results from a phase 1b study in patients with wAMD, DME and RVO

 

Sunday, September 8, 2019
9:48am CEST
Presentation by Pravin U. Dugel, MD

Free Paper Session

Title: Extended durability in exudative retinal diseases using a new class of molecules: novel anti-VEGF antibody biopolymer conjugate KSI-301: first-time results of the phase 1b study in patients with wAMD, DME and RVO